Show notes
While researchers originally explored sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide (GLP)-1 receptor agonists for their impact on blood glucose, the two classes of agents were unexpectedly found to have cardiovascular benefits. In this podcast, Ralph Brindis, MD, MPH, interviews Laurence Sperling, MD, about implementing SGLT2 inhibitors and GLP-1 receptor agonists into the treatment of patients with cardiovascular disease and diabetes. For more, click here: www.consultant360.com/cardiology



